(Q41853897)

English

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

scientific article published on 22 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 October 2017

Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia (English)

1 reference

Europe PubMed Central

13 October 2017

0 references

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

Kalifa A Bojang

object named as

Kalifa Bojang

1

0 references

Paul J. Milligan

object named as

Paul Milligan

2

0 references

Margaret Pinder

3

object named as

Margaret Pinder

1 reference

Europe PubMed Central

13 October 2017

W Ripley Ballou

10

object named as

W Ripley Ballou

1 reference

Europe PubMed Central

13 October 2017

Opokua Ofori-Anyinam

6

object named as

Opokua Ofori-Anyinam

1 reference

Europe PubMed Central

13 October 2017

7

object named as

Marc Lievens

1 reference

Europe PubMed Central

13 October 2017

author name string

Tom Doherty

4

1 reference

Europe PubMed Central

13 October 2017

Amanda Leach

5

1 reference

Europe PubMed Central

13 October 2017

Kent Kester

8

1 reference

Europe PubMed Central

13 October 2017

Kurt Schaecher

9

1 reference

Europe PubMed Central

13 October 2017

Joe Cohen

11

1 reference

Europe PubMed Central

13 October 2017

publication date

22 April 2009

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

5

1 reference

Europe PubMed Central

13 October 2017

4

1 reference

Europe PubMed Central

13 October 2017

242-247

1 reference

Europe PubMed Central

13 October 2017

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Immunization against hepatitis B--what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Comparison of two simple methods for determining malaria parasite density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

5 June 2018

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3787299

18 August 2018

Over a decade of experience with a yeast recombinant hepatitis B vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19276646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B vaccination: how long does protection last?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19276646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/HV.5.4.7050

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41853897&oldid=1928905595"